Gene Therapy
Study findings on gene therapy are outlined in reports from University of Ottawa
Published in Pharma Investments, Ventures and Law Weekly, August 9th, 2009
"Despite the promise of proangiogenic gene therapy most clinical trials have failed to show benefit for the primary end point analysis. The NOGA angiogenesis Revascularization Therapy: assessment by RadioNuclide imaging (NORTHERN) trial was a double-blind, placebo-controlled study of intramyocardial vascular endothelial growth factor (VEGF165) gene therapy versus placebo, involving seven sites across Canada, designed to overcome major limitations of previous proangiogenic gene therapy trials," researchers in Ottawa, Canada report.
"A total of 93 patients with refractory Canadian Cardiovascular Society (CCS) class 3 or 4 anginal symptoms were randomized to receive 2,000...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- A.P. Pharma, Inc.
A.P. Pharma Receives Nasdaq Notice of Non-Compliance; Company to Request Hearing - AAUW
AAUW Supports Confirmation of Judge Sotomayor - Addus HomeCare Corporation
Addus HomeCare Corporation Files Registration Statement - American Academy of Actuaries
Actuaries: Federal Long-Term Care Legislation Falls Short on Coverage Goals - American Association of Homes and Services for the Aging
Energy and Commerce Committee Advances Long-Term Services and Supports in Health Care Reform - American Civil Liberties Union
DHS Continues State and Local Immigration Enforcement Program Without Meaningful Changes - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
